An FDA advisory panel recommended approving canagliflozin (Invokana), a novel type 2 diabetes drug . Part of a class of SGLT2 inhibitors, the drug blocks blood glucose from being reabsorbed by the kidney, expelling it via urine. If approved, canagliflozin would be the first of its kind on the market. While the panel voted 10-5 in favor of approving the drug, several concerns were raised, including early cardiovascular events and stroke. Several panelists expressed the need for a cardiovascular outcomes study before the drug is approved. The decision will head to the FDA next.

Keywords: Blood Glucose, Diabetes Mellitus, Type 2, Glucosides, Kidney, Stroke, Thiophenes

< Back to Listings